Embargo: 28 April 2016 at 01:15 CEST
21 to 24 May in Florence, Italy
Sophia Antipolis 28 April 2016: New European Society of Cardiology (ESC) heart failure guidelines are set to be launched at Heart Failure 2016 and the 3rd World Congress on Acute Heart Failure in Florence, Italy. The world’s leading heart failure congress is the main annual meeting of the Heart Failure Association (HFA) of the ESC. It takes place 21 to 24 May in the historic sixteenth century Fortezza da Basso.
Professor Gerasimos Filippatos, HFA president, said: “Journalists at the congress will be the first to hear the latest clinical advice in the 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure, which will be revealed on day one of the congress. Subsequent sessions are devoted to specific aspects of the guidelines including acute heart failure, co-morbidities, arrhythmias and devices, and chronic heart failure – providing plenty of material for stories.”
Highly anticipated late breaking science will be presented in three sessions and feature state of the art discoveries from clinical trials, registries and basic science studies. More than 2 000 abstracts and clinical cases were submitted for presentation which is a new record and promises top quality research and news for the press. A highlights session will summarise the best findings of the abstract programme, selected and presented by experts. The full scientific programme is available here.
This year’s event is expected to host more delegates than ever before, with 5 000 set to attend. The event attracts numerous professions, including cardiologists, basic scientists, cardiac nurses, intensivists, anaesthesiologists, and emergency room physicians. Members of the press should register now.
The successful World Congress on Acute Heart Failure returns this year with debates, abstracts, and late breaking trials. Professor Filippatos said: “This is the place for the media to hear cutting edge developments in the fast moving area of acute heart failure.”
A novel session will see three clinical cases enacted in virtual patients created for the congress. Experts will guide the audience through these challenging cases and share their feedback and take-home messages.
During four days packed with science there will be more than 100 scientific sessions and contributions from over 300 international leaders in the field. Industry representatives will present innovations and discuss products in the pipeline. The basic and translational science programme has been enhanced with nine pre-arranged sessions with renowned experts plus breakthrough abstract presentations. A local track features six sessions in Italian and English and is organised in collaboration with societies and experts from Italy.
During the inaugural session, Karl Swedberg will give the Eugene Braunwald lecture on the success of neurohormonal and heart rate control in the treatment of heart failure. Luigi Tavazzi will give the Philip Poole Wilson lecture on new scenarios in medical science during the young investigator award session on basic and translational science.
A new HFA Career Cafe will be held on Saturday morning giving young heart failure specialists, who have applied ahead of the congress, the chance to receive face to face career advice and recommendations from three world renowned experts.
The congress theme is “Heart Failure: State of the Art” and reflects the launch of the new guidelines. Recommendations on the diagnosis and management of acute and chronic heart failure with drugs and devices, all based on the most up to date evidence, will be presented and discussed for the first time.
Professor Filippatos said: “Sign up now to get the latest on hot topics in acute and chronic heart failure at the biggest international meeting in the specialty.”
Also don’t miss the first public presentation of the 2016 European Guidelines on cardiovascular disease prevention in clinical practice. Be the first to know what the Task Force says by attending the session dedicated to this topic on Tuesday 24 May.
ENDS
Our mission: To reduce the burden of cardiovascular disease.